In the United States, where the number of confirmed cases has passed the 3 million mark, with more than 50,000 new cases a day, the health system is overwhelmed and vaccines will be a lifesaver.
On July 10, David Rach, an American man who was the first subject to receive the coVID-19 vaccine at the University of Maryland Medical Center, said he had successfully developed antibodies, according to media reports.
Ricky took part in a double-blind trial of the coVID-19 vaccine at the University of Maryland Medical Center in May and developed antibodies after two doses of the vaccine, the report said.
Vaccine maker Pfizer inc. said last week that early indications from the trial in which Rich was involved were that the growth of antibodies stimulated by the vaccine was equal to or greater than that of the patient’s antibodies, meaning they had already been produced.
Because it was a double-blind trial, Rich wasn’t sure if he had been given the real vaccine or saline.
But he had a mild reaction to the second vaccination and was convinced that he was one of the few people in the world to have been vaccinated against the coronavirus.
He will be tested again in October to see if he still has antibodies.
Pfizer is one of several companies racing to develop a vaccine.
If all goes well, the company has said it will produce 100 million doses by the end of this year and more than 1 billion doses next year.